{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:47Z","timestamp":1787009927222,"version":"build-2736575974"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen-Cilag France"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Lung cancer is the third most frequent cancer in France. It has a poor prognosis when patients are diagnosed at advanced stages. Low-dose computed tomography (LDCT) can detect early-stage cancer. In addition, blood-based biomarkers could help select patients for lung cancer screening or manage indeterminate lung nodules. The objective of this study is to assess the efficacy and cost-effectiveness of lung cancer screening in the French context including LDCT and biomarkers. A microsimulation model calibrated for France was used to compare four strategies: no screening, biennial LDCT, biennial LDCT followed by biomarkers, and biennial screening with biomarkers followed by LDCT. Screening eligibility included age (50\u201374) and smoking history (&gt;15 cigarettes\/day over 25 years, or 10 cigarettes\/day over 30 years, or former smokers who quit less than 10 years ago). A 25% participation rate was assumed. Direct medical costs were estimated from the perspective of the French health system. Cost and outcomes were discounted at 2.5%. Screening decreased lifetime lung cancer mortality from 2 to 12% depending on the participation rate, leading to an increase in both life years and quality-adjusted life years (QALY). Considering cost effectiveness, LDCT screening was associated with an incremental cost-effectiveness ratio of \u20ac7629 per QALY in comparison to the absence of screening. Sensitivity analyses were all favorable to LDCT-based screening strategies. Biennial LDCT screening could be an effective and cost-effective strategy in France even at a 25% participation rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cej.0000000000000973","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:00:56Z","timestamp":1747742456000},"page":"273-280","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and cost-effectiveness of lung cancer screening in France with low-dose computed tomography"],"prefix":"10.1097","volume":"35","author":[{"given":"Henri","family":"Leleu","sequence":"first","affiliation":[{"name":"Public Health Expertise, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Berkovitch","sequence":"additional","affiliation":[{"name":"Public Health Expertise, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bonastre","sequence":"additional","affiliation":[{"name":"Bureau Biostatistique et Epid\u00e9miologie, Gustave Roussy, Universit\u00e9 Paris-Saclay"},{"name":"INSERM, Universit\u00e9 Paris-Saclay, CESP U1018 Oncostat, labelis\u00e9 Ligue contre le cancer, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Caramella","sequence":"additional","affiliation":[{"name":"Radiology Department, Groupe Hospitalier Paris Saint Joseph, H\u00f4pital Marie Lannelongue, Le Plessis-Robinson"},{"name":"BIOMAPS UMR 1281, Universit\u00e9 Paris-Saclay, Inserm, CNRS, CEA, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Giroux-Leprieur","sequence":"additional","affiliation":[{"name":"Department of Respiratory Diseases and Thoracic Oncology, Universit\u00e9 Paris-Saclay, UVSQ, EA 4340 BECCOH, APHP-H\u00f4pital Ambroise Par\u00e9, Boulogne-Billancourt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Lef\u00e8vre","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, Issy-les-Moulineaux, Issy-les-Moulineaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernelle","family":"Lavaud","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gustave Roussy Cancer Center, University of Paris Saclay, Villejuif"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Todea","sequence":"additional","affiliation":[{"name":"Janssen-Cilag, Issy-les-Moulineaux, Issy-les-Moulineaux"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[{"name":"Unit\u00e9 d\u2019Oncologie Thoracique, Service de Pneumologie, H\u00f4pital Cochin, Assistance Publique des H\u00f4pitaux de Paris, Universit\u00e9, Paris"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hofman","sequence":"additional","affiliation":[{"name":"IHU RespirERA, FHU OncoAge, Laboratoire de Pathologie Clinique et Exp\u00e9rimentale, BB-0033-00025, H\u00f4pital Pasteur 1, Universit\u00e9 C\u00f4te d\u2019Azur, Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0140-6736(22)01694-4","article-title":"Lung cancer screening.","volume":"401","author":"Adams","year":"2023","journal-title":"Lancet"},{"issue":"Suppl 5","key":"R2-20260327","doi-asserted-by":"crossref","first-page":"e1S","DOI":"10.1378\/chest.12-2345","article-title":"Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.","volume":"143","author":"Alberg","year":"2013","journal-title":"Chest"},{"issue":"Suppl 1","key":"R3-20260327","first-page":"S14","article-title":"Chapter 2: birth-cohort-specific estimates of smoking behaviors for the U.S. population.","volume":"32","author":"Anderson","year":"2012","journal-title":"Risk Anal"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.lungcan.2018.06.007","article-title":"Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS).","volume":"124","author":"Andreas","year":"2018","journal-title":"Lung Cancer"},{"key":"R5-20260327","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1954.1","article-title":"The age distribution of cancer and a multi-stage theory of carcinogenesis.","volume":"8","author":"Armitage","year":"1954","journal-title":"Br J Cancer"},{"key":"R6-20260327","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/thoraxjnl-2015-207221","article-title":"The British Thoracic Society guidelines on the investigation and management of pulmonary nodules.","volume":"70","author":"Baldwin","year":"2015","journal-title":"Thorax"},{"key":"R7-20260327","first-page":"230","article-title":"Augmentation r\u00e9cente du tabagisme en France: principaux r\u00e9sultats du Barom\u00e8tre sant\u00e9, France, 2010.","volume":"20-21","author":"Beck","year":"2011","journal-title":"Bull Epid\u00e9miol Hebd"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41416-022-02026-8","article-title":"Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes.","volume":"128","author":"Behar Harpaz","year":"2023","journal-title":"Br J Cancer"},{"key":"R9-20260327","first-page":"159","article-title":"Estimation nationale de l\u2019incidence et de la mortalit\u00e9 par cancer en France entre 1980 et 2005.","volume":"56","author":"Belot","year":"2008","journal-title":"Institut de veille sanitaire Saint-Maurice (France)"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2018.11.008","article-title":"Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.","volume":"127","author":"Chouaid","year":"2019","journal-title":"Lung Cancer"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"129","DOI":"10.21037\/amj.2017.08.24","article-title":"International Early Lung Cancer Action Program: update on lung cancer screening and the management of CT screen-detected findings.","volume":"2","author":"Chung","year":"2017","journal-title":"AME Med J"},{"key":"R13-20260327","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.rmr.2015.09.008","article-title":"[Relationship between primary lung cancer and tobacco consumption. Results of the KBP-2010-CPHG study by the French College of General Hospital Respiratory Physicians].","volume":"33","author":"Co\u00ebtmeur","year":"2016","journal-title":"Rev Mal Respir"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/M19-0322","article-title":"Cost-effectiveness analysis of lung cancer screening in the United States.","volume":"171","author":"Criss","year":"2019","journal-title":"Ann Intern Med"},{"key":"R15-20260327","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.rmr.2013.10.644","article-title":"\u00c9volution en 10ans du cancer bronchique non \u00e0 petites cellules en fonction du sexe. R\u00e9sultats de l\u2019\u00e9tude KBP-2010-CPHG du Coll\u00e8ge des pneumologues des h\u00f4pitaux g\u00e9n\u00e9raux.","volume":"31","author":"Debieuvre","year":"2014","journal-title":"Rev Mal Respir"},{"key":"R16-20260327","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.lanepe.2022.100492","article-title":"Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): results of three French consecutive nationwide prospective cohorts\u2019 studies.","volume":"22","author":"Debieuvre","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"R18-20260327","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2020.05.004","article-title":"Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.","volume":"135","author":"Du","year":"2020","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"key":"R19-20260327","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for lung cancer: US Preventive Services Task Force recommendation statement.","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"R20-20260327","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jamaoncol.2021.4932","article-title":"Update of incidence, prevalence, survival, and initial treatment in patients with non\u2013small cell lung cancer in the US.","volume":"7","author":"Ganti","year":"2021","journal-title":"JAMA Oncol"},{"key":"R21-20260327","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.rmr.2017.10.001","article-title":"[First treatment strategies in the 2 years following lung cancer diagnosis. ESCAP-2011-CPHG, a real-life study carried out in French general hospitals].","volume":"34","author":"Grivaux","year":"2017","journal-title":"Rev Mal Respir"},{"key":"R22-20260327","first-page":"9798","article-title":"Tabagisme: estimation de la pr\u00e9valence d\u00e9clar\u00e9e, barom\u00e8tre sant\u00e9, France, 2004-2005.","volume":"22","author":"Guilbert","year":"2005","journal-title":"Bull \u00c9pid\u00e9miol Hebd"},{"key":"R26-20260327","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2214\/AJR.11.7146","article-title":"Mammography screening: a new estimate of number needed to screen to prevent one breast cancer death.","volume":"198","author":"Hendrick","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"R27-20260327","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s10198-021-01326-9","article-title":"General population normative data for the EQ-5D-3L in the five largest European economies.","volume":"22","author":"Janssen","year":"2021","journal-title":"Eur J Health Econ"},{"issue":"Suppl 1","key":"R28-20260327","first-page":"S51","article-title":"Chapter 5: actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation.","volume":"32","author":"Jeon","year":"2012","journal-title":"Risk Anal"},{"key":"R30-20260327","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1001\/jama.2021.0377","article-title":"Screening for lung cancer with low-dose computed tomography: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"325","author":"Jonas","year":"2021","journal-title":"JAMA"},{"key":"R31-20260327","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/M13-2316","article-title":"Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.","volume":"160","author":"de Koning","year":"2014","journal-title":"Ann Intern Med"},{"key":"R32-20260327","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial.","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"key":"R33-20260327","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2015.10.015","article-title":"Costs of non-small cell lung cancer in the Netherlands.","volume":"91","author":"van der Linden","year":"2016","journal-title":"Lung Cancer"},{"key":"R34-20260327","first-page":"317","article-title":"Analysis of lung cancer incidence in the Nurses\u2019 Health and the Health Professionals\u2019 follow-up studies using a multistage carcinogenesis model.","volume":"19","author":"Meza","year":"2008","journal-title":"Cancer Causes Control"},{"key":"R35-20260327","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1001\/jama.2021.1077","article-title":"Evaluation of the benefits and harms of lung cancer screening with low-dose computed tomography: modeling study for the US Preventive Services Task Force.","volume":"325","author":"Meza","year":"2021","journal-title":"JAMA"},{"key":"R36-20260327","doi-asserted-by":"crossref","first-page":"330","DOI":"10.7326\/M13-2771","article-title":"Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"},{"key":"R37-20260327","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1148\/radiology.175.3.2343122","article-title":"Low-dose CT of the lungs: preliminary observations.","volume":"175","author":"Naidich","year":"1990","journal-title":"Radiology"},{"key":"R38-20260327","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/thoraxjnl-2016-209825","article-title":"Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial.","volume":"72","author":"Paci","year":"2017","journal-title":"Thorax"},{"key":"R39-20260327","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1002\/cncr.28326","article-title":"The national lung screening trial: results stratified by demographics, smoking history, and lung cancer histology.","volume":"119","author":"Pinsky","year":"2013","journal-title":"Cancer"},{"key":"R40-20260327","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/eurpub\/ckv158","article-title":"Cost-effectiveness of screening for lung cancer with low-dose computed tomography: a systematic literature review.","volume":"26","author":"Puggina","year":"2016","journal-title":"Eur J Public Health"},{"key":"R41-20260327","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40258-016-0226-5","article-title":"Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review.","volume":"14","author":"Raymakers","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"key":"R42-20260327","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jms.8.3.125","article-title":"Screening and the number needed to treat.","volume":"8","author":"Richardson","year":"2001","journal-title":"J Med Screen"},{"key":"R43-20260327","first-page":"441","article-title":"Rapport 21-02. Le d\u00e9pistage du cancer du poumon par scanner thoracique faible dose (STFD) reste non justifi\u00e9, mais peut \u00eatre utile pour un bilan de sant\u00e9 des fumeurs.","volume":"205","author":"Sancho-Garnier","year":"2021","journal-title":"Bull Acad Natl M\u00e9d"},{"issue":"Suppl 1","key":"R44-20260327","first-page":"S85","article-title":"Chapter 7: description of MISCAN-lung, the Erasmus MC lung cancer microsimulation model for evaluating cancer control interventions.","volume":"32","author":"Schultz","year":"2012","journal-title":"Risk Anal"},{"key":"R45-20260327","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3747\/co.26.4555","article-title":"Cost-of-illness study for non-small-cell lung cancer using real-world data.","volume":"26","author":"Seung","year":"2019","journal-title":"Curr Oncol"},{"key":"R46-20260327","first-page":"7","article-title":"Cancer statistics, 2019.","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R47-20260327","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22690","article-title":"Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.","volume":"22","author":"Snowsill","year":"2018","journal-title":"Health Technol Assess"},{"key":"R48-20260327","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jtho.2019.05.044","article-title":"Lung cancer incidence and mortality with extended follow-up in the national lung screening trial.","volume":"14","year":"2019","journal-title":"J Thorac Oncol"},{"key":"R49-20260327","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lungcan.2018.05.008","article-title":"Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking \u2013 a modelling study.","volume":"121","author":"Tomonaga","year":"2018","journal-title":"Lung Cancer"},{"key":"R50-20260327","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1001\/jamaoncol.2021.4942","article-title":"Cost-effectiveness evaluation of the 2021 US Preventive Services Task Force recommendation for lung cancer screening.","volume":"7","author":"Toumazis","year":"2021","journal-title":"JAMA Oncol"},{"key":"R51-20260327","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2020.03.015","article-title":"Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.","volume":"143","author":"Veronesi","year":"2020","journal-title":"Lung Cancer"},{"key":"R52-20260327","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CPM.0b013e31827a30c1","article-title":"Risks of transthoracic needle biopsy: how high?","volume":"20","author":"Wiener","year":"2013","journal-title":"Clin Pulm Med"}],"container-title":["European Journal of Cancer Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000973","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:00:56Z","timestamp":1774591256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CEJ.0000000000000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cej.0000000000000973","relation":{},"ISSN":["0959-8278","1473-5709"],"issn-type":[{"value":"0959-8278","type":"print"},{"value":"1473-5709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}